Paper42458505
Multimodal magnetic resonance imaging in neuroblastoma chemotherapy: a narrative review.
Lu X and 2 others. World J Surg Oncol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Multimodal magnetic resonance imaging in neuroblastoma chemotherapy: a narrative review. Papers, record 42458505. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42458505
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neuroblastoma | Major topic |
| Multimodal Imaging | Major topic |
| Magnetic Resonance Imaging | Major topic |
| Humans | |
| Prognosis | |
| Dynamic Contrast Enhanced Magnetic Resonance Imaging | |
| Diffusion Magnetic Resonance Imaging |
Source PubMed
References102
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35401536 | Using a Gene Network of Pyroptosis to Quantify the Responses to Immunotherapy and Prognosis for Neuroblastoma Patients. | Front Immunol | 2022 | https://conductscience.org/library/papers/35401536 | PubMed |
| 2 | 31163505 | Update on Whole-body MRI in Musculoskeletal Applications. | Semin Musculoskelet Radiol | 2019 | https://conductscience.org/library/papers/31163505 | PubMed |
| 3 | 26761540 | MIBG in Neuroblastoma Diagnostic Imaging and Therapy. | Radiographics | 2016 | https://conductscience.org/library/papers/26761540 | PubMed |
| 4 | 37150742 | Outcomes and Histological Variations of Neuroblastoma and Ganglioneuroblastoma with Paraneoplastic Syndromes. | Am Surg | 2023 | https://conductscience.org/library/papers/37150742 | PubMed |
| 5 | 28471719 | Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28471719 | PubMed |
| 6 | 34156482 | [Radiological imaging of neuroblastoma]. | Radiologe | 2021 | https://conductscience.org/library/papers/34156482 | PubMed |
| 7 | 29110068 | Prognostic value of metabolic indices and bone marrow uptake pattern on preoperative 18F-FDG PET/CT in pediatric patients with neuroblastoma. | Eur J Nucl Med Mol Imaging | 2018 | https://conductscience.org/library/papers/29110068 | PubMed |
| 8 | 12195491 | MRI-diffusion imaging of neuroblastomas: first results and correlation to histology. | Eur Radiol | 2002 | https://conductscience.org/library/papers/12195491 | PubMed |
| 9 | 34462986 | Differentiating Benign from Malignant Renal Tumors Using T2- and Diffusion-Weighted Images: A Comparison of Deep Learning and Radiomics Models Versus Assessment from Radiologists. | J Magn Reson Imaging | 2022 | https://conductscience.org/library/papers/34462986 | PubMed |
| 10 | 39702399 | GD2-targeted theranostics of neuroblastoma with [64Cu]Cu/[177Lu]Lu-hu3F8. | Eur J Nucl Med Mol Imaging | 2025 | https://conductscience.org/library/papers/39702399 | PubMed |
| 11 | 25519453 | Variations in apparent diffusion coefficient values following chemotherapy in pediatric neuroblastoma. | Diagn Interv Radiol | 2015 | https://conductscience.org/library/papers/25519453 | PubMed |
| 12 | 30701332 | Quantitative DWI predicts event-free survival in children with neuroblastic tumours: preliminary findings from a retrospective cohort study. | Eur Radiol Exp | 2019 | https://conductscience.org/library/papers/30701332 | PubMed |
| 13 | 32196144 | Magnetic Nanoparticles in Cancer Therapy and Diagnosis. | Adv Healthc Mater | 2020 | https://conductscience.org/library/papers/32196144 | PubMed |
| 14 | 34167847 | Mediastinal neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: Pathology review and diagnostic approach. | Semin Diagn Pathol | 2022 | https://conductscience.org/library/papers/34167847 | PubMed |
| 15 | 35435953 | Immunotherapy of Neuroblastoma: Facts and Hopes. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35435953 | PubMed |
| 16 | 35689207 | Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells. | Mol Cancer | 2022 | https://conductscience.org/library/papers/35689207 | PubMed |
| 17 | 38039964 | ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. | Cancer Cell | 2023 | https://conductscience.org/library/papers/38039964 | PubMed |
| 18 | 38146213 | MR Imaging of Pediatric Neuroblastoma: Is Gadolinium Enhancement Necessary for Evaluation of Image-Defined-Risk Factors? | Can Assoc Radiol J | 2024 | https://conductscience.org/library/papers/38146213 | PubMed |
| 19 | 36240450 | The role of ADC value and Ki-67 index in predicting the response to neoadjuvant chemotherapy in advanced stages of olfactory neuroblastoma. | Br J Radiol | 2022 | https://conductscience.org/library/papers/36240450 | PubMed |
| 20 | 39189819 | Harnessing the therapeutic potential of phytochemicals in neuroblastoma. | Biofactors | 2025 | https://conductscience.org/library/papers/39189819 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42458505
GET https://conductscience.org/api/papers/v1/42458505/references?page=2